147 related articles for article (PubMed ID: 18825163)
1. Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia.
Hammarsten J; Damber JE; Karlsson M; Knutson T; Ljunggren O; Ohlsson C; Peeker R; Smith U; Mellström D
Prostate Cancer Prostatic Dis; 2009; 12(2):160-5. PubMed ID: 18825163
[TBL] [Abstract][Full Text] [Related]
2. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer.
Hammarsten J; Högstedt B
Eur J Cancer; 2005 Dec; 41(18):2887-95. PubMed ID: 16243513
[TBL] [Abstract][Full Text] [Related]
3. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia.
Dahle SE; Chokkalingam AP; Gao YT; Deng J; Stanczyk FZ; Hsing AW
J Urol; 2002 Aug; 168(2):599-604. PubMed ID: 12131317
[TBL] [Abstract][Full Text] [Related]
4. Insulin-resistance and benign prostatic hyperplasia: the connection.
Vikram A; Jena G; Ramarao P
Eur J Pharmacol; 2010 Sep; 641(2-3):75-81. PubMed ID: 20553919
[TBL] [Abstract][Full Text] [Related]
5. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia.
Ozden C; Ozdal OL; Urgancioglu G; Koyuncu H; Gokkaya S; Memis A
Eur Urol; 2007 Jan; 51(1):199-203; discussion 204-6. PubMed ID: 16806666
[TBL] [Abstract][Full Text] [Related]
6. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia.
Hammarsten J; Högstedt B; Holthuis N; Mellström D
Prostate Cancer Prostatic Dis; 1998 Mar; 1(3):157-162. PubMed ID: 12496910
[TBL] [Abstract][Full Text] [Related]
7. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.
Hammarsten J; Högstedt B
Eur Urol; 2001 Feb; 39(2):151-8. PubMed ID: 11223674
[TBL] [Abstract][Full Text] [Related]
8. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia.
Nandeesha H; Koner BC; Dorairajan LN; Sen SK
Clin Chim Acta; 2006 Aug; 370(1-2):89-93. PubMed ID: 16516184
[TBL] [Abstract][Full Text] [Related]
9. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans.
Gupta A; Gupta S; Pavuk M; Roehrborn CG
Urology; 2006 Dec; 68(6):1198-205. PubMed ID: 17169643
[TBL] [Abstract][Full Text] [Related]
10. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer.
Hammarsten J; Högstedt B
Blood Press; 2004; 13(1):47-55. PubMed ID: 15083641
[TBL] [Abstract][Full Text] [Related]
11. Lower urinary tract symptoms, obesity and the metabolic syndrome.
Moul S; McVary KT
Curr Opin Urol; 2010 Jan; 20(1):7-12. PubMed ID: 19904208
[TBL] [Abstract][Full Text] [Related]
12. [Benign prostatic hyperplasia (BPH) and metabolic syndrome: a single comorbidity].
Colombeau P
Ann Urol (Paris); 2006 Mar; 40 Spec No 1():7-10. PubMed ID: 16649583
[No Abstract] [Full Text] [Related]
13. Benign prostatic hyperplasia: does lifestyle play a role?
Barnard RJ; Aronson WJ
Phys Sportsmed; 2009 Dec; 37(4):141-6. PubMed ID: 20048551
[TBL] [Abstract][Full Text] [Related]
14. Low 25-OH vitamin D is associated with benign prostatic hyperplasia.
Haghsheno MA; Mellström D; Behre CJ; Damber JE; Johansson H; Karlsson M; Lorentzon M; Peeker R; Barret-Connor E; Waern E; Sundh V; Ohlsson C; Hammarsten J
J Urol; 2013 Aug; 190(2):608-14. PubMed ID: 23399651
[TBL] [Abstract][Full Text] [Related]
15. Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen.
Ho CK; Nanda J; Chapman KE; Habib FK
J Endocrinol; 2008 Jun; 197(3):483-91. PubMed ID: 18492814
[TBL] [Abstract][Full Text] [Related]
16. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
[TBL] [Abstract][Full Text] [Related]
17. Baldness, benign prostate hyperplasia, prostate cancer and androgen levels.
Faydaci G; Bilal E; Necmettin P; Fatih T; Asuman O; Uğur K
Aging Male; 2008 Dec; 11(4):189-92. PubMed ID: 19172550
[TBL] [Abstract][Full Text] [Related]
18. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
19. Serum resistin levels in benign prostate hyperplasia and non-metastatic prostate cancer: possible role in cancer progression.
Housa D; Vernerova Z; Heracek J; Cechak P; Rosova B; Kuncova J; Haluzik M
Neoplasma; 2008; 55(5):442-6. PubMed ID: 18665756
[TBL] [Abstract][Full Text] [Related]
20. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review.
Alcaraz A; Hammerer P; Tubaro A; Schröder FH; Castro R
Eur Urol; 2009 Apr; 55(4):864-73. PubMed ID: 19027219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
